Instituto de Biología Molecular y Celular (IBMC), Miguel Hernández University, 03202, Elche, Spain.
Appl Microbiol Biotechnol. 2013 Apr;97(7):3007-16. doi: 10.1007/s00253-012-4403-7. Epub 2012 Sep 23.
Although some DNA vaccines have proved to be very efficient in field trials, their authorisation still remains limited to a few countries. This is in part due to safety issues because most of them contain viral regulatory sequences to driving the expression of the encoded antigen. This is the case of the only DNA vaccine against a fish rhabdovirus (a negative ssRNA virus), authorised in Canada, despite the important economic losses that these viruses cause to aquaculture all over the world. In an attempt to solve this problem and using as a model a non-authorised, but efficient DNA vaccine against the fish rhabdovirus, viral haemorrhagic septicaemia virus (VHSV), we developed a plasmid construction containing regulatory sequences exclusively from fish origin. The result was an "all-fish vector", named pJAC-G, containing 5' and 3' regulatory sequences of β-acting genes from carp and zebrafish, respectively. In vitro and in vivo, pJAC-G drove a successful expression of the VHSV glycoprotein G (G), the only antigen of the virus conferring in vivo protection. Furthermore, and by means of in vitro fusion assays, it was confirmed that G protein expressed from pJAC-G was fully functional. Altogether, these results suggest that DNA vaccines containing host-homologous gene regulatory sequences might be useful for developing safer DNA vaccines, while they also might be useful for basic studies.
尽管一些 DNA 疫苗在田间试验中已被证明非常有效,但它们的批准仍然限于少数几个国家。这部分是由于安全问题,因为它们大多数都含有病毒调节序列来驱动编码抗原的表达。这种情况仅适用于针对鱼类弹状病毒(一种负单链 RNA 病毒)的唯一 DNA 疫苗,尽管这些病毒在世界范围内给水产养殖造成了巨大的经济损失,但该疫苗已在加拿大获得批准。为了解决这个问题,并使用针对鱼类弹状病毒(病毒性出血性败血症病毒,VHSV)的非批准但有效的 DNA 疫苗作为模型,我们开发了一种含有仅来自鱼类来源的调节序列的质粒构建体。结果是一种名为 pJAC-G 的“全鱼载体”,它含有来自鲤鱼和斑马鱼的 β-肌动蛋白基因的 5'和 3'调节序列。在体外和体内,pJAC-G 成功地表达了 VHSV 糖蛋白 G(G),这是赋予体内保护作用的病毒的唯一抗原。此外,通过体外融合试验证实,从 pJAC-G 表达的 G 蛋白是完全功能性的。总之,这些结果表明,含有宿主同源基因调节序列的 DNA 疫苗可能有助于开发更安全的 DNA 疫苗,同时也可能有助于基础研究。